Company Performance - Precision BioSciences reported a quarterly loss of $2.13 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of -2,266.67% [1] - The company posted revenues of $0.02 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 99.87%, compared to revenues of $49.9 million a year ago [2] - Over the last four quarters, Precision BioSciences has not surpassed consensus EPS or revenue estimates [2] Stock Movement and Outlook - Precision BioSciences shares have increased by approximately 26.3% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.38 on $11 million in revenues for the coming quarter and -$2.77 on $35.7 million in revenues for the current fiscal year [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Precision BioSciences belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of Precision BioSciences may be influenced by the overall industry outlook, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]
Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates